Table 3 Temporomandibular disorders pain characteristics of the study population after 6 months’ treatment
From: Antinuclear antibody and rheumatoid factor positivity in temporomandibular disorders
|  | Total patients (n = 257) | Male patients (n = 51) | Female patients (n = 206) | ||||||
|---|---|---|---|---|---|---|---|---|---|
ANA/RF (+) (n = 39) | ANA/RF (−) (n = 218) | P-value | ANA/RF (+) (n = 4) | ANA/RF (−) (n = 47) | P-value | ANA/RF (+) (n = 35) | ANA/RF (−) (n = 171) | P-value | |
CMOa | 42 (36–48) | 45 (40–50) | 0.024* | 43 (37–53) | 50 (45–53) | 0.347 | 41 (35–48) | 44 (40–48) | 0.088 |
MMOa | 44 (38–49) | 46 (42–51) | 0.069 | 47 (38–54) | 52 (47–54) | 0.246 | 44 (38–49) | 45 (40–49) | 0.325 |
Pain on openingb | 17/39 (43.6%) | 54/205 (26.3%) | 0.035 | 1/4 (25.0%) | 13/45 (28.9%) | 1.000 | 16/34 (47.1%) | 41/157 (26.1%) | 0.022* |
Capsule palpationb | 9/39 (23.1%) | 53/205 (25.9%) | 0.842 | 2/4 (50.0%) | 9/45 (20.0%) | 0.214 | 6/33 (18.2%) | 42/157 (26.8%) | 0.381 |
Muscle palpation -masticatoryb | 12/39 (30.8%) | 72/205 (35.1%) | 0.714 | 3/4 (75.0%) | 13/45 (28.9%) | 0.096 | 8/33 (24.2%) | 58/157 (36.9%) | 0.227 |
NRS improvementb | 23/33 (69.7%) | 106/166 (63.9%) | 0.557 | 4/4 (100%) | 24/36 (66.7%) | 0.297 | 19/28 (67.9%) | 82/127 (64.6%) | 0.829 |